| Literature DB >> 27109632 |
Shin-Ichiro Ohno1, Karen Itano1, Yuichirou Harada1, Koutaro Asada1, Keiki Oikawa1, Mikie Kashiwazako1, Hikaru Okuyama1, Katsuyoshi Kumagai2, Masakatsu Takanashi1, Katsuko Sudo2, Norihiko Ikeda3, Masahiko Kuroda1.
Abstract
The innate cytokine response to nucleic acid is the most challenging problem confronting the practical use of nucleic acid medicine. The degree of stimulation of the innate cytokine response strongly depends on the length of the nucleic acid. In this study, we developed a 30-nucleotide single-strand RNA, termed "guide hairpin RNA (ghRNA, ghR)", that has a physiological function similar to that of miRNA and siRNA. The ghR caused no innate cytokine response either in vitro or in vivo. In addition, its structure does not contain a passenger strand seed sequence, reducing the unwanted gene repression relative to existing short RNA reagents. Systemic and local injection of ghR-form miR-34a (ghR-34a) suppressed tumor growth in a mouse model of RAS-induced lung cancer. Furthermore, Dicer and AGO2 are not required for ghR-34a function. This novel RNA interference (RNAi) technology may provide a novel, safe, and effective nucleic acid drug platform that will increase the clinical usefulness of nucleic acid therapy.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27109632 PMCID： PMC5088761 DOI： 10.1038/mt.2016.81
Source DB: PubMed Journal: Mol Ther ISSN： 1525-0016 Impact factor: 11.454